Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report

Stuart E. Lacy, Sharon L. Barrans, Philip A. Beer, Daniel Painter, Alexandra G. Smith, Eve Roman, Susanna L. Cooke, Camilo Ruiz, Paul Glover, Suzan J. L. Van Hoppe, Nichola Webster, Peter J. Campbell, Reuben M. Tooze, Russell Patmore, Cathy Burton, Simon Crouch, Daniel J. Hodson

Blood (2020) 135 (20): 1759–1771.

https://doi.org/10.1182/blood.2019003535

Published: 2020

Includes: Supplemental data

Journal Articles

The Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma As Determined By Whole Genome Expression Profiling on Paraffin Embedded Tissue Is Independently Associated with Reduced Overall and Progression Free Survival in the Rituximab Era: Results from the UK NCRI R-CHOP 14 v 21 Phase III Trial

Blood (2016) 128 (22): 1746.

https://doi.org/10.1182/blood.V128.22.1746.1746

Published: 2016

Journal Articles

Genome-Wide Methylation Analysis of Patients with Diffuse Large B Cell Lymphoma Treated on the UK NCRI R-CHOP 14 Vs 21 Trial

Andrea Kühnl, MD, Ridwan Shaikh, David Cunningham, Sharon L Barrans, Cathy H Burton, Andrew Jack, Mary Gleeson, Nicholas Counsell, Paul Smith, Oliver Schofield, David C. Linch, FRCP, Michael Hubank, PhD

Blood (2016) 128 (22): 1747.

https://doi.org/10.1182/blood.V128.22.1747.1747

Published: 2016

Journal Articles

Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression

Catherine A. Cargo, Nicola Rowbotham, Paul A. Evans, Sharon L. Barrans, David T. Bowen, Simon Crouch, Andrew S. Jack

Blood (2015) 126 (21): 2362–2365.

https://doi.org/10.1182/blood-2015-08-663237

Published: 2015

Includes: Supplemental data

Journal Articles

Response: Bone marrow involvement and outcome in Burkitt lymphoma and diffuse large B-cell lymphoma

Andrew S. Jack, Sharon L. Barrans, Wendi Qian, Sally P. Stenning, Graham M. Mead

Blood (2009) 114 (2): 486–487.

https://doi.org/10.1182/blood-2009-04-214627

Published: 2009

Journal Articles

TP53 Deletion in CLL: The Significance of Borderline Level Deletion

Sheila J.M. O’Connor, PhD, Kathryn R Turner, MSc, Bradley Dickinson, MSc, Sharon L Barrans, PhD, Roger G Owen, Andrew Jack, PhD, MB, Peter Hillmen, MBChB, PhD

Blood (2008) 112 (11): 4178.

https://doi.org/10.1182/blood.V112.11.4178.4178

Published: 2008

Journal Articles

Aberrant Co-Expression of Key Transcription Factors BCL6, IRF4 and FOXP1 Are Frequently Observed in Diffuse Large B-Cell Lymphoma

Maayke Boll, Sharon L Barrans, Charles S McManamy, Andrew S Jack

Blood (2008) 112 (11): 3761.

https://doi.org/10.1182/blood.V112.11.3761.3761

Published: 2008

Journal Articles

A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial)

Graham M. Mead, Sharon L. Barrans, Wendi Qian, Jan Walewski, John A. Radford, Max Wolf, Simon M. Clawson, Sally P. Stenning, Claire L. Yule, Andrew S. Jack

Blood (2008) 112 (6): 2248–2260.

https://doi.org/10.1182/blood-2008-03-145128

Published: 2008

Journal Articles

RAG1 and BRCA2 polymorphisms in non-Hodgkin lymphoma

Kathryn Scott, Peter J. Adamson, Sharon L. Barrans, Lisa J. Worrillow, Eleanor V. Willett, James M. Allan

Blood (2007) 109 (12): 5522–5523.

https://doi.org/10.1182/blood-2006-12-061572

Published: 2007

Journal Articles

Abortive Plasma Cell Differentiation with Loss of Mature B-Cell Phenotype in a Subset of Patients with De Novo Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma: Relevance of cMYC Rearrangements.

Matthew J. Cullen, MSc, Sharon L. Barrans, PhD, Stephen J. Richards, PhD, Andy C. Rawstron, PhD, Sheila J.M. O’Connor, PhD, Reuben M. Tooze, PhD, Roger G. Owen, MD, Andrew Jack, MD

Blood (2006) 108 (11): 4643.

https://doi.org/10.1182/blood.V108.11.4643.4643

Published: 2006

Journal Articles

Rearrangements of MALT1, IgH, FOXP1 , BCL3 and PAX5 Are Rare Events in Extranodal Marginal Zone Lymphoma in the UK.

Sharon L. Barrans, PhD, Kathryn Turner, MSc, Sheila J.M. O’Connor, PhD, Andrew S. Jack, MD, Roger G. Owen, MD

Blood (2006) 108 (11): 4639.

https://doi.org/10.1182/blood.V108.11.4639.4639

Published: 2006

Journal Articles

Expression of FOXP1 in a Poor Prognostic Sub-Group of DLBCL Is Associated with Deregulated Expression of AID.

James A.L. Fenton, DPhil, Sharon L. Barrans, PhD, Andrew S. Jack, PhD

Blood (2006) 108 (11): 2034.

https://doi.org/10.1182/blood.V108.11.2034.2034

Published: 2006

Journal Articles

A Highly Effective Model of Risk Assessment in Diffuse Large B Cell Lymphoma (DLBCL) Using Classification and Regression Tree (CART) Analysis.

Sharon L. Barrans, PhD, Alex Smith, PhD, Sheila J.M. O’Connor, PhD, Kathryn Turner, MSC, Russell Patmore, MD, Roger G. Owen, MD, Eve Roman, PhD, Andrew Jack, MD

Blood (2005) 106 (11): 1918.

https://doi.org/10.1182/blood.V106.11.1918.1918

Published: 2005

Journal Articles

Bi-Allelic Deletion of 13q14 Is Associated with Inferior Progression Free Survival Compared to Mono-Allelic 13q14 Deletion in B-Cell Chronic Lymphocytic Leukaemia.

Sheila J. O’Connor, PhD, Kathryn Turner, MSc, Sharon L. Barrans, PhD, Brad Dickinson, MSc, Andy C. Rawstron, PhD, Hazem Sayala, MD, Paul Moreton, MD, Roger G. Owen, MD, Andrew S. Jack, PhD, Peter Hillmen, PhD

Blood (2005) 106 (11): 2936.

https://doi.org/10.1182/blood.V106.11.2936.2936

Published: 2005

Journal Articles

Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome

Sharon L. Barrans, James A. L. Fenton, Alison Banham, Roger G. Owen, Andrew S. Jack

Blood (2004) 104 (9): 2933–2935.

https://doi.org/10.1182/blood-2004-03-1209

Published: 2004

Journal Articles

Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma

Sharon L. Barrans, Ian Carter, Roger G. Owen, Faith E. Davies, Russell D. Patmore, Andrew P. Haynes, Gareth J. Morgan, Andrew S. Jack

Blood (2002) 99 (4): 1136–1143.

https://doi.org/10.1182/blood.V99.4.1136

Published: 2002

NARROW

Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report

The Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma As Determined By Whole Genome Expression Profiling on Paraffin Embedded Tissue Is Independently Associated with Reduced Overall and Progression Free Survival in the Rituximab Era: Results from the UK NCRI R-CHOP 14 v 21 Phase III Trial

Genome-Wide Methylation Analysis of Patients with Diffuse Large B Cell Lymphoma Treated on the UK NCRI R-CHOP 14 Vs 21 Trial

Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression

Response: Bone marrow involvement and outcome in Burkitt lymphoma and diffuse large B-cell lymphoma

TP53 Deletion in CLL: The Significance of Borderline Level Deletion

Aberrant Co-Expression of Key Transcription Factors BCL6, IRF4 and FOXP1 Are Frequently Observed in Diffuse Large B-Cell Lymphoma

A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial)

RAG1 and BRCA2 polymorphisms in non-Hodgkin lymphoma

Abortive Plasma Cell Differentiation with Loss of Mature B-Cell Phenotype in a Subset of Patients with De Novo Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma: Relevance of cMYC Rearrangements.

Rearrangements of MALT1, IgH, FOXP1 , BCL3 and PAX5 Are Rare Events in Extranodal Marginal Zone Lymphoma in the UK.

Expression of FOXP1 in a Poor Prognostic Sub-Group of DLBCL Is Associated with Deregulated Expression of AID.

A Highly Effective Model of Risk Assessment in Diffuse Large B Cell Lymphoma (DLBCL) Using Classification and Regression Tree (CART) Analysis.

Bi-Allelic Deletion of 13q14 Is Associated with Inferior Progression Free Survival Compared to Mono-Allelic 13q14 Deletion in B-Cell Chronic Lymphocytic Leukaemia.

Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome

Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only